

New Clinical Trial Opportunity

• Relapsing Multiple Sclerosis

SiteRx is excited to announce the launch of a new clinical research study in partnership with Novartis Pharmaceuticals. Now available to all network providers



**Immediate
Patient Need**

500

ARTIOS is actively recruiting Phase III study, targeting patients with Relapsing Multiple Sclerosis

Clinical Trial Summary

- ARTIOS is a large Phase III b trial
- Patient population single arm, open-label study to evaluate ARTIOS treatment effectiveness and patient reported outcomes in patients with Relapsing MS transitioning from dimethyl fumarate or fingolimod therapy following 6 months of treatment.
- ARTIOS 20mg subcutaneous injections every 4 weeks up to 96 weeks

Key Inclusion Criteria

- Adults ages 18-60 diagnosed with Relapsing MS or Secondary Progressive MS
- Patients who suffered a relapse while being treated with fingolimod or dimethyl fumarate
- EDSS score from 0 to 4

Key Exclusion Criteria

- Primary Progressive MS or SPMS without disease activity
- Disease duration over 10 years
- Patients with an active chronic disease of the immune system other than MS
- Patients with neurological findings consistent with PML
- Consider dosage changing memory or other medication is a top reason for disqualification, but patients can stay on medication throughout the trial



**Patient Site
Options**

SiteRx is launching ARTIOS in Florida

Questions about ARTIOS?

Contact your Clinical Trial Advocate Today:
Hello@SiteRx.com